Vineti, a cell and gene therapy software and analytics company, received $13.8 million in capital from GE Ventures, Mayo Clinic Ventures and DFJ and LifeForce Capital. The investment will be used to grow its team and support the delivery of its cloud-based software designed to improve patient access, accelerate treatment delivery, and promote safety and regulatory compliance for individualized cell therapies.
 
Within the oncology market, approximately $5.7 billion was invested in cell and gene therapies this past year, with more than 800 clinical trials initiated worldwide. The first two CAR-T cell therapies are expected to launch later this year. While these therapeutics are advancing patient outcomes, they are extremely complex to produce and deliver. Legacy paper-driven processes in cell collection, therapeutic production and logistical delivery that have not kept pace with medical and digital innovation can limit their potential.
 
The Vineti platform is designed to integrate logistics, manufacturing and clinical data in an effort to improve product performance overall and enable faster, broader access for patients.
 
“Physicians, medical researchers and pharmaceutical companies are working together to develop successful therapies, transitioning from a one-size-fits-all model to individualized treatments for each patient. Now, the process for creating and delivering these treatments can be as innovative as the therapies themselves,” said Amy DuRoss, chief executive officer at Vineti. “We are developing the Vineti platform to help these treatments reach the patients who need them the most, and are confident the partnership between our advanced technologies and leading medical research will deliver better health outcomes across the globe.”
 
GE Ventures launched Vineti to bridge the technology gap between individualized cell therapies and production capabilities. Automating the production and delivery of these treatments can help connect the gene and cell therapies field with the broader healthcare system. GE Ventures, Mayo Clinic and DFJ have invested in Vineti to help ensure a clear, safe and efficient path forward in this field.
 
“There’s a serious discrepancy between the accelerated development of life-saving cancer therapies and the supporting technologies required to deliver these treatments,” said Risa Stack, general manager of New Business Creation at GE Ventures and Vineti board member. “Vineti’s dream team of leading industry pioneers and software engineers have formed the first company to align innovation in research with innovation in how next-generation therapies are produced and delivered, putting them on equal ground for the first time. GE Ventures is committed to supporting Vineti as it continues to revolutionize the way therapies are developed and delivered.”
 
Vineti’s co-founding executives—Ms. DuRoss; Heidi Hagen, chief strategy officer; Razmik Abnous, chief technology officer; and Malek Faham, chief science officer—are working directly with customers to develop and implement the Vineti cloud-based platform to address the requirements of each link in the individualized therapy value chain.
 
In addition to its software platform, Vineti provides analytics designed to improve manufacturing, value chain operations and compliance, as well as clinical and commercial operations.